The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02381457




Registration number
NCT02381457
Ethics application status
Date submitted
2/03/2015
Date registered
6/03/2015
Date last updated
29/01/2021

Titles & IDs
Public title
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Scientific title
SNP-based Microdeletion and Aneuploidy RegisTry
Secondary ID [1] 0 0
14-024-NPT
Universal Trial Number (UTN)
Trial acronym
SMART
Linked study record

Health condition
Health condition(s) or problem(s) studied:
22q11 Deletion Syndrome 0 0
DiGeorge Syndrome 0 0
Trisomy 21 0 0
Trisomy 18 0 0
Trisomy 13 0 0
Monosomy X 0 0
Sex Chromosome Abnormalities 0 0
Cri-du-Chat Syndrome 0 0
Angelman Syndrome 0 0
Prader-Willi Syndrome 0 0
1p36 Deletion Syndrome 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Mental Health 0 0 0 0
Learning disabilities
Neurological 0 0 0 0
Other neurological disorders
Human Genetics and Inherited Disorders 0 0 0 0
Down's syndrome
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Observational [Patient Registry]
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Pregnancies undergoing prenatal microdeletion screening - Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.

No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis.

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
22q11.2 Snp-based non-invasive prenatal screening test performance, including positive predictive value (PPV), specificity, and sensitivity
Timepoint [1] 0 0
3 years
Secondary outcome [1] 0 0
Combined microdeletion syndrome screening test performance
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
No call rate
Timepoint [2] 0 0
3 years
Secondary outcome [3] 0 0
Low fetal fraction aneuploidy risk refinement
Timepoint [3] 0 0
3 years
Secondary outcome [4] 0 0
Placental mosaicism exploration
Timepoint [4] 0 0
3 years
Secondary outcome [5] 0 0
Placental complications exploration
Timepoint [5] 0 0
3 years

Eligibility
Key inclusion criteria
* Singleton pregnancy
* Receiving Panorama prenatal screening test for both microdeletions (at least 22q11.2) and aneuploidy
* Planned hospital delivery
* Gestational age of = 9 weeks, 0 days based on clinical information and evaluation.
* Able to provide informed consent
Minimum age
18 Years
Maximum age
48 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Received results of the Panorama test prior to enrollment
* Organ transplant recipient
* Egg donor used

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal Prince Alfred - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
New Jersey
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Utah
Country [6] 0 0
Ireland
State/province [6] 0 0
Dublin
Country [7] 0 0
Spain
State/province [7] 0 0
Barcelona
Country [8] 0 0
Sweden
State/province [8] 0 0
Gothenburg
Country [9] 0 0
United Kingdom
State/province [9] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Natera, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
George Washington University
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
University of California, San Francisco
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Montefiore Medical Center
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Children's Hospital of Philadelphia
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peer Dar, MD
Address 0 0
Montefiore Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Pergament E, Cuckle H, Zimmermann B, Banjevic M, S... [More Details]
Journal Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagas... [More Details]
Journal Palomaki GE, Kloza EM, Lambert-Messerlian GM, Hadd... [More Details]
Journal Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek ... [More Details]
Journal Benn P, Cuckle H, Pergament E. Genome-wide fetal a... [More Details]
Journal Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian... [More Details]
Journal Sparks AB, Struble CA, Wang ET, Song K, Oliphant A... [More Details]
Journal Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, ... [More Details]
Journal Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Ma... [More Details]
Journal Nicolaides KH, Syngelaki A, del Mar Gil M, Quezada... [More Details]
Journal Samango-Sprouse C, Banjevic M, Ryan A, Sigurjonsso... [More Details]
Journal Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Z... [More Details]
Journal Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmerman... [More Details]
Journal Vora NL, O'Brien BM. Noninvasive prenatal testing ... [More Details]
Journal Taglauer ES, Wilkins-Haug L, Bianchi DW. Review: c... [More Details]
Journal Knight M, Redman CW, Linton EA, Sargent IL. Sheddi... [More Details]
Journal Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Dem... [More Details]
Journal Amos-Landgraf JM, Ji Y, Gottlieb W, Depinet T, Wan... [More Details]
Journal Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, ... [More Details]
Journal Tranquilli AL, Emanuelli M. The thrombophilic fetu... [More Details]
Journal Faiz AS, Ananth CV. Etiology and risk factors for ... [More Details]